3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Multiple Myeloma
2
Lung Neoplasms
2
Carcinoma
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Breast Neoplasms
1
Interventions
Fluorouracil
21
Oxaliplatin
17
Leucovorin
17
Bevacizumab
17
Irinotecan
13
Panitumumab
12
Cetuximab
12
IFL protocol
9
Capecitabine
9
pembrolizumab
7
Radiotherapy
7
Pemetrexed
5
Gemcitabine
5
labetuzumab
3
conatumumab
3
Cisplatin
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
5,11-methenyltetrahydrohomofolate
3
130-nm albumin-bound paclitaxel
3
vatalanib
2
trametinib
2
spartalizumab
2
pegfilgrastim
2
ganitumab
2
encorafenib
2
dostarlimab
2
Ramucirumab
2
Paclitaxel
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rectal Neoplasms
×
L-BLP25
×
Clear all
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts